SNDX - Kura Oncology: Ziftomenib's Path To AML Market Widens

2024-01-31 08:30:00 ET

Summary

• Kura Oncology's Progress: Since September, Kura secured a $150 million private placement; stock surged 136%.
• Clinical Advances: Ziftomenib shows promise in Phase 1 AML trial; particularly effective in NPM1-mutant AML.
• Financial Health: Strong short-term liquidity with a high current ratio; long-term stability requires cautious monitoring due to the nature of development-stage biotechnology.
• Investment Recommendation: Maintain "Buy" on KURA; promising ziftomenib data in AML, but monitor for future developments and risks.

Kura Oncology At a Glance

A lot has changed with Kura Oncology ( KURA ) since my initial "Buy" recommendation in September, which was based on ziftomenib's potential in NPM1-mutant AML....

For further details see: